U.S. Markets closed

ERYTECH Pharma S.A. (ERYP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.7500-0.3500 (-6.86%)
At close: 4:00PM EDT
Sign in to post a message.
  • S
    Shlomo
    (ERYP-DD) Market Cap $129 M / Cash balance $60 M / Potential Blockbuster Drug targeting Pancreatic Cancer with final Phase 3 readout (positive phase 3 interim analysis released in Q1) and potential BLA filing for acute lymphoblastic leukemia ALL indication expected THIS Quarter / Undiscovered low float stock = Could run toward $50 and even higher on positive results and approval . More Informations below :

    Market Cap $129 Million
    Cash: $60 Million
    Price: $5

    Shares Out 26.4 Million

    Presentation
    https://erytech.com/wp-content/uploads/210505_ERYTECH_Corporate_Presentation_May_2021.pdf

    Key News Flow and Milestones Expected Over the Next 12 Months

    ▪Final results from TRYbeCA-1 Phase-3 trial of eryaspase in 2L PAC (Q4 2021)
    ▪Potential eryaspase BLA filing for ALL (2H 2021)
    ▪Initial datafrom the randomized Phase 2 TRYbeCA-2 trial of eryaspase in TNBC (Q4 2021)
    ▪Determination of the maximum tolerated dose in rESPECT, Phase 1 IST in 1L PAC (2H2021)

    Major Shareholders:

    BVF Partners LP...24,91 %
    RA Capital Management LLP...11,15 %
    Auriga Partners...5,68 %
    JP Morgan...3,27 %
    Recordati Orphan Drugs...2,40 %
    Bullish
  • L
    Leonidas
    9x av volume. Something up?
  • J
    Johan
    Problem is their ATM. They print more shares every day. Till now ...27 million.....a few months ago...they had 20 million. Ok?

    27 million shares means nothing.....if they get an approval from FDA by the end of this year

    But as you know....only 1 out of 10 gets approved.
    So its a gamble....but its cheap.
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 6.43% to 5.05
  • c
    c
    Back under $6
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 14.48% to 4.98
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 17.89% to 5.14
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is down 7.84% to 4.70
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 6.45% to 4.95
  • J
    Joujou29
    $BLRX conversation
    Hello All,
    very important point: do not confuse mOS /mPFS data for 1L cancer treatment (currently approved Abraxane and Onyvide options) with 2L treatments. 2L options are mostly under investigation currently so comparison is made on current phase 2 trials mostly.

    And just for you to know...$ERYP has the best results in 2L treatment as of now and it corresponds to 8,3 weeks (2,1 months) of mPFS and 6 months for mOS. This will certainly help assessing the upcoming $BLRX publication. In terms of OS, the best OS registered in phase 2 trials for 2L treatments is also the one from $ERYP with 6 months.
    To make it simple to understand the target to beat in the upcoming 2L results for Pancreatic Cancer:
    PFS : 3months
    OS: 6 months.
    Bullish
  • S
    Shlomo
    (ERYP-DD) Market Cap $105 M / Cash balance $51 M / Potential Blockbuster Drug targeting Pancreatic Cancer with Phase 3 readout in next Quarter and final Phase 2 results of the ALL trial expected THIS Quarter / Undiscovered low float stock = Could run toward ATH ($37+ ) and even higher on positive results .

    Market Cap $105 Million
    Cash: $51 Million
    Price: 5.60

    Shares Out 18.9 Million

    https://assets.wallstreet-online.de/_media/8763/board/20201014151904-screenshot-2020-10-14-presentation-powerpoint-200.png

    Latest Presentation
    https://erytech.com/wp-content/uploads/200923_ERYTECH_Corporate_Presentation_Sept_2020.pdf

    Final results of Phase 2 investigator-sponsored NOPHO trial in second-line acute lymphoblastic leukemia (Q4 2020)

    Complete enrollment and interim (superiority) analysis in TRYbeCA-1, the Phase 3 clinical trial in second-line metastatic pancreatic cancer (respectively Q4 2020 and Q1 2021)

    Major Shareholders:

    BVF Partners LP...24,91 %
    RA Capital Management LLP...11,15 %
    Auriga Partners...5,68 %
    JP Morgan...3,27 %
    Recordati Orphan Drugs...2,40 %
  • V
    V
    why is the stock so cheap?
  • c
    c
    Time to buy back or wait for a lower entry price?
  • A
    Andy
    More good news again. Not sure why there is no interest in this stock but I expect that will change
  • D
    Dan
    anybody home? CC and we have 4 shares traded? is this dead money
  • A
    Andy
    Nice news this morning. Hope it bodes well for Phase III in second line
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 5.62% to 5.45
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is down 8.53% to 5.35
  • c
    c
    Why are they borrowing the money now, vs a line of credit? Borrow the money to just have it sit in a bank account earning 0% interest while paying interest expense of 1.75%?
  • Y
    Yahoo Finance Insights
    ERYTECH Pharma is up 10.09% to 6.33